IGF-1 DES
Also known as: Des(1-3) IGF-1, Des IGF-1, IGF-1 Des
IGF-1 DES is a truncated analog of insulin-like growth factor-1 that lacks the first three amino acids, making it 10 times more potent than regular IGF-1 and highly localized in action.
IGF-1 DES is a 7372 Da research peptide. IGF-1 DES is a truncated analog of insulin-like growth factor-1 that lacks the first three amino acids, making it 10 times more potent than regular IGF-1 and highly localized in action.
Also called: Des(1-3) IGF-1, Des IGF-1, IGF-1 Des
7372
Molecular Weight
Daltons
2
Strong Evidence
benefits
3
Studies Cited
peer-reviewed
20-40
Typical Dose
mcg
Overview
IGF-1 DES represents a modified form of insulin-like growth factor-1 where the first three amino acids (glycine-proline-glutamate) have been removed. This structural modification creates a peptide with dramatically enhanced potency and localized action compared to full-length IGF-1. The truncated structure prevents binding to IGF binding proteins, allowing direct interaction with IGF-1 receptors and resulting in more concentrated effects at injection sites. Research shows IGF-1 DES demonstrates superior muscle-building properties and localized tissue growth compared to its full-length counterpart. The peptide maintains the core growth-promoting functions of IGF-1 while offering enhanced bioavailability and site-specific action, making it valuable for targeted research applications in muscle development and tissue repair studies.
Key Takeaways: IGF-1 DES
- Strongest evidence supports IGF-1 DES for enhanced protein synthesis and satellite cell proliferation
- Research doses typically range from 20 to 40 mcg via subcutaneous
- 2 benefits with strong evidence, 2 moderate, 2 preliminary
- Half-life: 20-30 minutes
- 3 cited research studies in this guide
Mechanism of Action
IGF-1 DES binds directly to IGF-1 receptors without interference from IGF binding proteins due to its truncated N-terminus. Upon receptor binding, it activates the PI3K/Akt signaling pathway, promoting protein synthesis through mTOR activation. The peptide stimulates satellite cell proliferation and differentiation, leading to muscle fiber hyperplasia and hypertrophy. Its shortened structure creates enhanced receptor affinity and localized action, concentrating growth effects at injection sites while minimizing systemic exposure.
Research Benefits
IGF-1 DES at a Glance
IGF-1 DES binds directly to IGF-1 receptors without interference from IGF binding proteins due to its truncated N-terminus.
Enhanced Protein Synthesis
Strong EvidenceThe peptide activates mTOR signaling pathways more effectively than full-length IGF-1, increasing amino acid uptake and ribosomal protein production. This leads to accelerated muscle protein synthesis rates and improved nitrogen retention.
Satellite Cell Proliferation
Strong EvidenceIGF-1 DES stimulates dormant satellite cells to enter the cell cycle, promoting myoblast proliferation and differentiation. This process increases the number of available nuclei for muscle growth and repair.
Localized Muscle Growth
Moderate EvidenceIGF-1 DES promotes site-specific muscle development by directly targeting IGF-1 receptors at injection locations. The peptide stimulates satellite cell activation and muscle protein synthesis in targeted areas, leading to localized hypertrophy without systemic effects.
Improved Recovery
Moderate EvidenceThe peptide accelerates tissue repair by promoting cellular regeneration and reducing muscle damage markers. IGF-1 DES enhances the repair of microscopic muscle tears through increased protein synthesis and anti-inflammatory effects.
Hyperplasia Induction
PreliminaryUnlike hypertrophy alone, IGF-1 DES may promote the creation of new muscle fibers through satellite cell fusion. This hyperplastic effect potentially increases the total number of muscle fibers rather than just their size.
Nerve Tissue Protection
PreliminaryResearch indicates IGF-1 DES may have neuroprotective properties, promoting nerve cell survival and axon regeneration. The peptide supports neuronal growth factor expression and protects against excitotoxic damage.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Muscle growth research | 20–40 mcg | subcutaneous |
| Localized tissue development | 40–80 mcg | intramuscular |
| Recovery studies | 20–60 mcg | subcutaneous |
Frequency
Daily injections
Timing
Post-workout or pre-sleep for research protocols
Cycle Length
4-6 weeks maximum
Research Notes
- 1Rotate injection sites to prevent localized tissue changes
- 2Use immediately after reconstitution due to short stability
- 3Start with lower doses to assess response
- 4Monitor for signs of hypoglycemia during research
- 5Bilateral injections recommended for symmetrical studies
Reconstitution Guide
Standard Reconstitution
Vial Size
1000 mg
Bacteriostatic Water
2 mL
Concentration
5000 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
IGF-1 DES vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 2 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C refrigerated. 72 hours after reconstitution.
Storage Temperature
2-8°C refrigerated
Shelf Life
72 hours after reconstitution
Important Notes
- •Use bacteriostatic water for reconstitution
- •Extremely fragile peptide - handle with care
- •Mix gently, never shake vigorously
- •Use within 3 days of mixing for optimal potency
- •Store powder at -20°C before reconstitution
IGF-1 DES Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
IGF-1 DES Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Hypoglycemia and blood sugar fluctuations
- !Injection site reactions and tissue changes
- !Potential organ enlargement with prolonged use
- !Headaches and dizziness
- !Joint pain and stiffness
- !Fluid retention and edema
- !Carpal tunnel syndrome symptoms
- !Insulin resistance development
- !Localized tissue deformation
Potential Interactions
- ⚡Insulin and diabetes medications - enhanced hypoglycemic effects
- ⚡Corticosteroids - may reduce IGF-1 DES effectiveness
- ⚡Growth hormone - synergistic effects requiring dose adjustment
- ⚡Thyroid hormones - altered glucose metabolism
- ⚡Beta-blockers - masked hypoglycemia symptoms
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Des(1-3)IGF-I is a potent inducer of muscle hypertrophy in rats
Study demonstrated that IGF-1 DES produced greater muscle growth than full-length IGF-1 when administered locally, with effects lasting weeks after treatment cessation.
Local expression of IGF-1 isoforms in normal and dystrophic muscle
Research showed IGF-1 DES had superior local tissue effects compared to other IGF-1 variants, with enhanced satellite cell activation and reduced binding protein interference.
Insulin-like growth factor-I isoforms and muscle growth
Comprehensive review of IGF-1 variants showed DES form had unique properties for localized muscle development due to reduced binding protein affinity.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
IGF-1 DES lacks the first three amino acids found in full-length IGF-1, making it unable to bind to IGF binding proteins. This creates 10 times greater potency and highly localized effects at injection sites.
IGF-1 DES has a very short half-life of 20-30 minutes, which contributes to its localized action. The peptide must be used immediately after reconstitution for maximum effectiveness.
Research suggests IGF-1 DES can promote both temporary and potentially lasting changes through hyperplasia (new muscle fiber creation) and satellite cell activation, though long-term effects require further study.
IGF-1 DES should be injected into the specific muscle groups targeted for research. Subcutaneous injection near target muscles or direct intramuscular injection are common protocols.
Yes, IGF-1 DES can lower blood glucose levels similar to insulin. Research protocols should monitor for hypoglycemia and consider glucose availability during studies.
Initial cellular responses occur within hours, but measurable tissue changes typically appear after 7-14 days of consistent administration in research settings.
IGF-1 DES should not be mixed with other compounds due to its fragile structure. Each peptide should be reconstituted and administered separately.
The peptide degrades rapidly at room temperature. Once reconstituted, it must be kept refrigerated and used within 72 hours to maintain potency.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.